Prostrate cancer drug welcomed
A hi-tech prostate cancer drug that offers hope to men who have run out of treatment options became available in the UK. It will be trialled in the capital today.
New cancer drug 'positive impact' on quality of life
A new hi-tech prostate cancer drug has already demonstrated a 'positive impact on the quality of life', the Institute of Cancer Research said today, as the treatment trials in the capital.
Professor Johann de Bono from the institute, who led the Affirm trial, said:
"Enzalutamide is a much needed development in prostate cancer treatment and will provide a new option for the increasing number of men with advanced prostate cancer in the UK whose disease has become resistant to first-line hormonal treatments and who have had docetaxel chemotherapy.
"Enzalutamide has already demonstrated a positive impact on quality of life whilst increasing the life-span of patients with this common disease.
"It's use will bring significant benefits, establishing it as a key component of advanced prostate cancer treatment in the UK."
More top news
-
Police create dispersal zones around south London raves
The unlicensed events unfolded on Saturday night at Clapham Common and Tooting Bec Common.
-
Second man dies in River Thames drowning
A 37 year old man who was taken to hospital after getting into difficulty in a stretch of water near Maidenhead has died.
-
Teenager jailed for throwing six year old boy off Tate balcony
Jonty Bravery, who is mentally ill, has been jailed for 15 years after throwing a six year old boy from the Tate modern balcony.